Medicine
Rapiblyk 280 mg powder for injection
Rapiblyk 280 mg powder for injection is a prescription medicine containing Landiolol for intravenous use, marketed by AOP Orphan Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store unreconstituted product at 20°C to 25°C (68ºF to 77ºF), with excursions…
Key facts
- Active ingredient (INN)
- Landiolol
- Brand
- Rapiblyk
- Strength
- 280 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- AOP Orphan Pharmaceuticals
- Manufacturer
- AOP Orphan Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store unreconstituted product at 20°C to 25°C (68ºF to 77ºF), with excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). Store in the original carton to protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C07AB14 Landiolol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 August 2025
- Identifiers
- RxCUI 2712074, 2712079DailyMed set ID 27e7f20f-78a4-f1a9-e063-6394a90ae465NDC 84381-110Application NDA217202
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, single-dose | 84381-110-01 | AOP Orphan Pharmaceuticals | 7 August 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 22 November 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Landiolol is a beta-adrenergic blocker indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia. MedsAcross supplies Landiolol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LandiololFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RAPIBLYK prescribing information (AOP Orphan Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Rapiblyk 280 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.